Literature DB >> 147324

Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis.

K Sahashi, A G Engel, J M Linstrom, E H Lambert, V A Lennon.   

Abstract

Rats immunized with purified torpedo acetylcholine receptor (AChR) plus adjuvants developed chronic experimental autoimmune myasthenia gravis (EAMG) after day 28. Forelimb muscles from EAMG rats 29 to 103 days after immunization and from control animals were used for the ultrastructural localization of IgG and C3. IgG was demonstrated with rabbit anti-rat IgG followed by treatment with peroxidase-labeled staphylococcal protein A; and C3 with peroxidase-labeled rabbit anti-rat C3, or with unlabeled rabbit anti-rat C3 followed by peroxidase-labeled protein A. In EAMG rats both IgG and C3 were localized on the terminal expansions of the junctional folds, where AChR is known to be located, and on detached, degenerated parts of the folds in the synaptic space. Background staining was negligible. The findings provide unambiguous evidence for a destructive autoimmune reaction involving the postsynaptic membrane in EAMG, implicate the complement system in this reaction and show that detachment of the tips of the junctional folds is one way by which immune complexes, and AChR, are eliminated from the postsynaptic membrane. The immuno-electron microscopic findings in chronic EAMG closely resemble those described in human myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 147324     DOI: 10.1097/00005072-197803000-00008

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  27 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 5.  Myasthenia gravis--current concepts.

Authors:  C Herrmann; J M Lindstrom; J C Keesey; D G Mulder
Journal:  West J Med       Date:  1985-06

Review 6.  The role of complement in experimental autoimmune myasthenia gravis.

Authors:  Linda L Kusner; Henry J Kaminski
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

8.  Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

Authors:  C M Gomez; R L Wollmann; D P Richman
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

9.  Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.

Authors:  A Bionda; M H De Baets; S J Tzartos; J M Lindstrom; W O Weigle; A N Theophilopoulos
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

10.  A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Authors:  J M Heckmann; H Uwimpuhwe; R Ballo; M Kaur; V B Bajic; S Prince
Journal:  Genes Immun       Date:  2009-08-13       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.